Skip to main content
NCBI home page
Atencion Primaria logoLink to Atencion Primaria
. 2013 Apr 5;30(1):29–31. [Article in Spanish] doi: 10.1016/S0212-6567(02)78960-9

¿Son directamente aplicables las tablas de Framingham a la población mediterránea?

F Cordón Granados 1, P Solanas Saura 1,*
PMCID: PMC7679559  PMID: 12106577

The content is available as a PDF (300.8 KB).

Bibliografía

  • 1.Pérez G., Pena A., Sala J., Roset P.N., Masià R., Marrugat J., the REGICOR Investigators Acute myocardial infarction case fatality, incidence and mortality rates in a population registry in Gerona, Spain, 1990–1992. Int J Epidemiol. 1998;27:599–604. doi: 10.1093/ije/27.4.599. [DOI] [PubMed] [Google Scholar]
  • 2.Artaud-Wild S.M., Connor S.L., Sexton G., Connor W.E. Differences in coronary mortality can be explained by differences in cholesterol and saturated fat intakes in 40 countries but not in France and Finland. Circulation. 1993;88:2771–2779. doi: 10.1161/01.cir.88.6.2771. [DOI] [PubMed] [Google Scholar]
  • 3.TunstallPedoe H., Kuulasmaa K., Amouyel P., Arveiler D., Rajakangas A.M., Pajak A. WHO MONICA Project. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and casefatality rates in 38 populations from 21 countries in four continents. Circulation. 1994;90:583–612. doi: 10.1161/01.cir.90.1.583. [DOI] [PubMed] [Google Scholar]
  • 4.Masià R., Pena A., Marrugat J., Sala J., Vila J.S., Pavesi M. High prevalence of cardiovascular risk factors in Gerona, Spain, a province with a low myocardial infarction incidence. J Epidemiol Community Health. 1998;52:707–715. doi: 10.1136/jech.52.11.707. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Shepherd M.D., Stuart M., Cobbe M.D. Prevención de la cardiopatía coronaria con pravastatina en varones con hipercolesterolemia. N Engl J Med. 1995;333:1301–1307. [Google Scholar]
  • 6.Downs J.R., Clearfield M., Weis S. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615–1622. doi: 10.1001/jama.279.20.1615. [DOI] [PubMed] [Google Scholar]
  • 7.Marrugat J., Masià R., Pérez G. 20 anys del REGICOR, Regis-tre Gironí del Cor. 1978–1998. Generalitat de Catalunya; Girona: 1998. [Google Scholar]
  • 8.Masià R., Pena A., Marrugat J., Sala J., Vila J.S., Pavesi M., the REGICOR investigators High prevalence of cardiovascular risk factors in Gerona, Spain, a province with a low myocardial infarction incidence. J Epidemiol Community Health. 1998;52:707–715. doi: 10.1136/jech.52.11.707. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Verschuren M., Jacobs D., Bloemberg B. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the Seven Countries Study. JAMA. 1995;274:131–136. [PubMed] [Google Scholar]
  • 10.Anderson K., Castelli W., Levy D. Cholesterol and Mortality. 30 years of follow-up from the Framingham Study. JAMA. 1987;257:2176–2180. doi: 10.1001/jama.257.16.2176. [DOI] [PubMed] [Google Scholar]
  • 11.Smith G.D., Song F., Sheldon T. Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ. 1993;306:1367–1373. doi: 10.1136/bmj.306.6889.1367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Pharoah P., Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without preexisting coronary heart disease: life table method applied to health authority population. BMJ. 1996;312:1443–1448. doi: 10.1136/bmj.312.7044.1443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Shepherd J. Cost effectiveness of lowering cholesterol. BMJ. 1996;313:1142.. doi: 10.1136/bmj.313.7065.1142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.McMurray J.V., Morrison C.E. Study greatly underestimates the cost effectiveness of statin treatment. BMJ. 1996;313:1142.. doi: 10.1136/bmj.313.7065.1142a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Masters P., Shetty A. Statin treatment should be started early. Br Med J. 1996;313:1143.. doi: 10.1136/bmj.313.7065.1143a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Freemantle N., Barbour R., Johnson R., Marchment M., Kennedy A. The use of statins: a case of misleading priorities? BMJ. 1997;315:826–828. doi: 10.1136/bmj.315.7112.826. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Caro J., Klittich W., McGuire A. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ. 1997;315:1577–1582. doi: 10.1136/bmj.315.7122.1577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Brotons C., Maiques A. ¿Debe administrarse terapia farmacológica hipolipemiante en normolipémicos o hiperlipémicos leves con factores de riesgo coronario? Argumentos en contra. Rev Esp Cardiol. 1997;49:486–491. [PubMed] [Google Scholar]

Articles from Atencion Primaria are provided here courtesy of Elsevier

RESOURCES